RecruitingPhase 2NCT07211542

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

75 participants

Start Date

Nov 7, 2025

Study Type

INTERVENTIONAL

Conditions

Moderate-to-severe Atopic Dermatitis

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
Have atopic dermatitis at screening.

Exclusion Criteria5

Hypersensitivity to the study drug or any ingredient in the study drug.
Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
Has malignancy or has a history of malignancy.
Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
Females who are pregnant or lactating.

Interested in this trial?

Get notified about updates and connect with the research team.